[{"id":"9d48ede6-b99d-4cb5-b344-2b1fdbb0d237","acronym":"","url":"https://clinicaltrials.gov/study/NCT02629692","created_at":"2021-01-18T12:47:10.989Z","updated_at":"2024-07-02T16:35:31.435Z","phase":"Phase 1/2","brief_title":"Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML Therapies","source_id_and_acronym":"NCT02629692","lead_sponsor":"Sun Pharma Advanced Research Company Limited","biomarkers":" ABL1 • BCR","pipe":"","alterations":" ","tags":["ABL1 • BCR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vodobatinib (SCO - 088)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 122","initiation":"Initiation: 04/25/2017","start_date":" 04/25/2017","primary_txt":" Primary completion: 08/01/2026","primary_completion_date":" 08/01/2026","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2023-10-27"}]